AHF begins its open letter to Cipla by reiterating its original claim- which Cipla has yet to refute-that the generic manufacturer is offering many of its HIV/AIDS medicines at significantly lower prices in African than in India: "The simple truth is that Cipla is charging too much for its drugs in India and its pricing is depriving Indians living with HIV/AIDS of access to lifesaving treatment ... Cipla is charging much more for anti-retroviral (ARV) drugs in India than they do in Africa."
A chart included in the ad compares the private price Cipla offers in
India to the government or non-governmental organization price offered in
Africa and the private price offered in Uganda (where AHF operates free
treatment clinics). The results are startling: Cipla offers Duovir-N, a
combination of three generic anti-retroviral drugs, for two times as much
in India as it does in Africa and almost one-and-a-half times as much than
in Uganda. The price Cipla offers for Triomune, a combination of three
generic anti-retroviral drugs, is three times as much in India as offered
in Africa and two-and-a-half times as much as Cipla charges for the same
drug in Uganda. Finally, the price Cipla offers for Efavir, a two-in-one
anti-retroviral combination, is three times as much in India as offered in
Africa or twice as much than Cipla charges in Uganda. Bottom line: All
three of these potential lifesaving generic ARV combinations by Cipla are
priced (or offered) at an average of two to three times less in Africa than
they are priced (or offered) in India; as such, the steeper pr
'/>"/>
| SOURCE AIDS Healthcare Foundation Copyright©2007 PR Newswire. All rights reserved |